 Injections, Subcutaneous
"Injections, Subcutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
| Descriptor ID |
D007279
|
| MeSH Number(s) |
E02.319.267.530.620
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Injections, Subcutaneous".
Below are MeSH descriptors whose meaning is more specific than "Injections, Subcutaneous".
This graph shows the total number of publications written about "Injections, Subcutaneous" by people in this website by year, and whether "Injections, Subcutaneous" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 | | 1997 | 0 | 4 | 4 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 7 | 7 | | 2002 | 0 | 4 | 4 | | 2003 | 0 | 4 | 4 | | 2004 | 0 | 10 | 10 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 5 | 5 | | 2007 | 0 | 6 | 6 | | 2008 | 0 | 3 | 3 | | 2009 | 0 | 4 | 4 | | 2010 | 0 | 6 | 6 | | 2011 | 1 | 3 | 4 | | 2012 | 0 | 3 | 3 | | 2013 | 0 | 2 | 2 | | 2014 | 0 | 4 | 4 | | 2016 | 1 | 5 | 6 | | 2017 | 0 | 2 | 2 | | 2018 | 0 | 3 | 3 | | 2019 | 0 | 3 | 3 | | 2020 | 0 | 7 | 7 | | 2021 | 0 | 6 | 6 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 2 | 2 | | 2024 | 0 | 3 | 3 | | 2025 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Injections, Subcutaneous" by people in Profiles.
-
Misakian AL, Kelley CE, Sullivan EA, Chang JJ, Singh G, Kokosa S, Avila J, Cooper H, Liang JW, Botzheim B, Quint M, Jeevananthan A, Chi E, Harmer M, Hiatt L, Kowalewski M, Steinberg B, Tausinga T, Tanner H, Ho TF, Mark B, Zenger B, Hu S, Gebregzabheir A, Penny JM, Loeb DF, Strickland T, Iwamoto SJ, Rothman MS, Hamnvik OR, Ariel D. Injectable Estradiol Use in Transgender and Gender-Diverse Individuals throughout the United States. J Clin Endocrinol Metab. 2025 Aug 07; 110(9):e2898-e2907.
-
Bonaca MP, Catarig AM, Hansen Y, Houlind K, Ramesh CK, Ludvik B, Nordanstig J, Rasouli N, Sourij H, Verma S. Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11; 10(8):728-737.
-
Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, Szarek M, Stroes ESG, Troquay R, Dorresteijn JAN, Fok H, Rider DA, Romano S, Wolski K, Rambaran C. Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA. 2024 12 17; 332(23):1992-2002.
-
Nicolosi C, Draganich C, Marzloff G. Subcutaneous Botulinum Toxin Type-A Injections for the Treatment of Central Neuropathic Pain in a Patient With Multiple Sclerosis - A Case Report. Pain Med Case Rep. 2024 07; 8(5):179-184.
-
Rothman MS, Ariel D, Kelley C, Hamnvik OR, Abramowitz J, Irwig MS, Soe K, Davidge-Pitts C, Misakian AL, Safer JD, Iwamoto SJ. The Use of Injectable Estradiol in Transgender and Gender Diverse Adults: A Scoping Review of Dose and Serum Estradiol Levels. Endocr Pract. 2024 Sep; 30(9):870-878.
-
Simpson EL, Guttman-Yassky E, Eichenfield LF, Boguniewicz M, Bieber T, Schneider S, Guana A, Silverberg JI. Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition. Allergy. 2023 11; 78(11):2875-2891.
-
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopec G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 04 20; 388(16):1478-1490.
-
Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Pérez M, Bismuth E, Dib S, Cho JI, Cox D. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. N Engl J Med. 2022 08 04; 387(5):433-443.
-
Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Häring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022 05; 28(6):910-924.
-
Yang B, Gelfanov VM, Perez-Tilve D, DuBois B, Rohlfs R, Levy J, Douros JD, Finan B, Mayer JP, DiMarchi RD. Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists. J Med Chem. 2021 04 22; 64(8):4697-4708.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|